Company
POLB +0.90%Poolbeg Pharma PLC
Market Cap: £64.0 Million
GBP as of Aug 2, 2026 | US$86.1 Million
$POLB +0.90% $POLB United Kingdom Healthcare Biotechnology UK Healthcare UK BiotechnologyPoolbeg Pharma PLC Market Capitalization Over Time
View HistoryEvolution of Poolbeg Pharma PLC market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a Phase-II ready p38 MAP Kinase inhibitor that reduces harmful inflammation in patients with severe forms of influenza; PredictViral Biomarker Platform, a tool for predicting severe diseases; and vaccine discovery platform, which are techniques used in human challenge models to identify vaccine candidates that drive preferential T-Cell immune responses. The company was formerly known as Orph Pharma Limited and changed its name to Poolbeg Pharma PLC in June 2021. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom.
Financials
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £0 |
| EBITDA | £-5,569,000 |
| Gross Profit TTM | £0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |